

JDS 44/1645

Docket No. 13761-7030

RADEMARK	ZQV		•
	Certificate of Mailing/Transmission (37 C.F.R. §	1.8(a)):	\mathbf{x}
the date indicated below in an envelope at	y certify that this paper and all enclosures are being deposited with the dddressed to the Assistant Commissioner for Patents, Washington D.C. eby certify that this paper and all enclosures are being sent via facsimi	ile on the date indicated belgw to the attention of 100	ECE
Examiner at Fac Dated: March 13, 2002	simile Noata.m/p.m. Name of Person Certifying: Printed Name: LAER BARRETT	faret/ \$ 20	K
		/290	D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE S

Applicant: Miller, et al.

Assignee:

University of Southern

California

Filing Date: September 27, 2001

Examiner: Unassigned Group Art Unit: 1644

Serial No.: 09/966,561
Title: TREATING

TREATING NEUROLOGICAL DISORDERS USING HUMAN

APOPTOSIS INHIBITING PROTEIN

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

With the new patent application submitted herewith (37 C.F.R. § 1.	.97(a))
--	---------

- Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
- Before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114.
- Before the mailing of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement:

02/22/2002 9MIKA991 00000071 501192 | 09986531

01 FC:105 160.00 CW

	the Commissioner is hereby authorized to charge Deposit Account No. 50-1192, Docket No. 13761-7030 for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.
	a statement as specified in 37 C.F.R. § 1.97(e) is provided below.
This Informati	on Disclosure Statement is filed:
	After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing, or after the mailing of a first Office Action after the filing of a request for continued examination, but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and
	the Commissioner is hereby authorized to charge Deposit Account No. [] for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.
	a statement as specified in 37 C.F.R. § 1.97(e) is provided below.
This Informati	on Disclosure Statement is filed:
	After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, but on or before the payment of an issue fee, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.
Pursuant to 37	C.F.R. § 1.97(e), the undersigned certifies that:
	Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
	No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
II. Copies of	the Cited Items:
	Copies of all of the items listed on the attached Form PTO-1449 are enclosed.
\boxtimes	Copies of only the following items listed on the attached Form PTO-1449 are enclosed: Items not marked with an asterisk.

	PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. 09/419,694, filed October 14, 1999 and relied upon in this application for an earlier filing date under 35 U.S.C. § 120. See 37 C.F.R. § 1.98(d).
	Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application
	are attached hereto.
Concise	are attached hereto. Explanation of Relevance:
Concise	

Conject of those items which are marked with an asterick (*) in the attached Form

IV. Conclusion:

III.

 \square

Citation of the above documents shall not be construed as:

- an admission that the documents are necessarily prior art with respect to the instant invention;
- 2. a representation that a search has been made, other than as described above; or
- an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. 50-1192 Docket No.: 50-1192, Docket No. 13761-7030 for any additional fees required in connection with the filling of this Information Disclosure Statement.

DATE: March 13, 2002

Respectfully submitted,

By DOM

Registration No. 43,999

McCutchen, Doyle, Brown & Enersen, LLP Three Embarcadero Center, 18th Floor San Francisco, California 94111

Telephone: (415) 393-2000 Telefax: (415) 393-2286